KRAS抑制劑全球市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球KRAS抑制劑市場預計將從2025年的6.1932億美元成長至2034年的18.9031億美元，2026年至2034年的複合年成長率（CAGR）為13.2%。該市場快速擴張的原因在於，人們越來越認知到KRAS突變是腫瘤治療的關鍵標靶。 KRAS突變與多種難治性癌症有關，尤其是某些肺癌、大腸直腸癌和胰臟癌。分子生物學和精準醫學的進步使研究人員能夠開發出選擇性抑制特定KRAS變異體的療法。分子診斷檢測的普及也有助於識別能夠從標靶治療中獲益的患者。對各種KRAS突變和抗藥性機制的持續臨床研究有望拓寬治療選擇，並創造巨大的市場機會。

針對特定KRAS突變的標靶抑制劑的出現是推動KRAS藥物成長要素。製藥公司正積極投資研發下一代分子，旨在提高治療反應率、克服後天抗藥性並應對其他KRAS突變。將KRAS抑制劑與其他標靶治療或免疫腫瘤療法合併使用的聯合治療也日益受到關注。生物標記檢測的日益普及有助於患者篩選和精準醫療。此外，癌症發生率的上升以及晚期癌症有效治療需求的不斷成長，也推動了對KRAS標靶藥物研發的持續投入。

鑑於研發管線正拓展至目前針對KRAS突變以外的領域，KRAS抑制劑的未來前景尤其光明。研究人員正致力於開發針對其他突變、延長療效持續時間和克服治療過程中潛在抗藥性的抑制劑。聯合治療可望顯著提升這些療法的臨床效用。此外，伴隨診斷和基因組分析在識別合適患者方面的重要性預計將日益凸顯。然而，製藥公司之間的競爭、臨床開發挑戰以及定價因素預計將對市場動態產生影響。總體而言，精準腫瘤學領域的持續創新有望為KRAS抑制劑保持強勁的成長勢頭。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球KRAS抑制劑市場：依藥物分類

• 市場分析、洞察與預測
• 索特拉西布
• 阿達格拉西布
• 迪瓦拉西布
• 奧羅莫拉西布
• RMC-6236
• KRAS G12D抑制劑
• 其他

第5章 全球KRAS抑制劑市場：依疾病適應症分類

• 市場分析、洞察與預測
• 非小細胞肺癌
• 結腸癌
• 胰臟癌
• 膽道癌
• 其他

第6章 全球KRAS抑制劑市場：依年齡層別分類

• 市場分析、洞察與預測
• 成人
• 兒童

第7章 全球KRAS抑制劑市場：按類型分類

• 市場分析、洞察與預測
• KRAS G12C抑制劑
• KRAS G12D抑制劑
• 其他

第8章 全球KRAS抑制劑市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 腸外

第9章 全球KRAS抑制劑市場：按分銷管道分類

• 市場分析、洞察與預測
• 醫院藥房
• 專科藥房
• 零售藥局和藥局
• 網路藥房

第10章 全球KRAS抑制劑市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第11章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第12章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Amgen Inc
  • Bristol Myers Squibb Company
  • Innovent Biologics Inc
  • InventisBio Co. Ltd
  • Jacobio Pharmaceuticals Group Co. Ltd
  • Revolution Medicines Inc
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly And Company
  • Astellas Pharma Inc
  • Bayer AG
  • Mirati Therapeutics Inc
  • Novartis AG
  • Pfizer Inc
  • Merck & Co. Inc
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson
  • AbbVie Inc
  • Genentech Inc
  • BeiGene Ltd

The global KRAS inhibitors market size is expected to reach USD 1890.31 Million in 2034 from USD 619.32 Million in 2025, growing at a CAGR of 13.2% during 2026-2034.This market is expanding rapidly due to growing recognition of KRAS mutations as important therapeutic targets in oncology. KRAS alterations are associated with several difficult-to-treat cancers, particularly certain forms of lung, colorectal, and pancreatic cancer. Advances in molecular biology and precision medicine have enabled researchers to develop therapies designed to selectively inhibit specific KRAS variants. Increasing availability of molecular diagnostic testing is helping identify eligible patients for targeted treatment. Continued clinical research into different KRAS mutations and resistance mechanisms is expected to broaden the therapeutic landscape and create significant opportunities.

The emergence of targeted inhibitors for specific KRAS mutations has become a major growth driver. Pharmaceutical companies are investing heavily in next-generation molecules designed to improve response rates, overcome acquired resistance, and address additional KRAS variants. Combination therapies involving KRAS inhibitors with other targeted or immuno-oncology treatments are also receiving increasing research attention. Growing adoption of biomarker testing is supporting patient selection and precision treatment. Furthermore, increasing cancer incidence and the unmet need for effective therapies in advanced cancers are encouraging continued investment in KRAS-focused drug development.

Future prospects are particularly strong as the pipeline expands beyond currently targeted KRAS variants. Researchers are investigating inhibitors designed to address additional mutations, improve durability, and overcome resistance that may emerge during treatment. Combination strategies could significantly expand the clinical utility of these therapies. Companion diagnostics and genomic profiling are also expected to become increasingly important for identifying appropriate patients. However, competition among drug developers, clinical development challenges, and pricing considerations will influence market dynamics. Overall, continued innovation in precision oncology is expected to sustain strong growth opportunities for KRAS inhibitors.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug

• Sotorasib
• Adagrasib
• Divarasib
• Olomorasib
• RMC-6236
• KRAS G12D Inhibitors
• Others

By Disease Indication

• Non-Small Cell Lung Cancer
• Colorectal Cancer
• Pancreatic Cancer
• Biliary Tract Cancer
• Others

By Age Group

• Adults
• Pediatric

By Type

• KRAS G12C Inhibitors
• KRAS G12D Inhibitors
• Others

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Retail & Drug Store Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Amgen Inc., Bristol Myers Squibb Company, Innovent Biologics Inc., InventisBio Co. Ltd., Jacobio Pharmaceuticals Group Co. Ltd., Revolution Medicines Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Astellas Pharma Inc., Bayer AG, Mirati Therapeutics Inc., Novartis AG, Pfizer Inc., Merck & Co. Inc., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Johnson & Johnson, AbbVie Inc., Genentech Inc., BeiGene Ltd.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL KRAS INHIBITORS MARKET: BY DRUG 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug
• 4.2. Sotorasib Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Adagrasib Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Divarasib Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Olomorasib Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. RMC-6236 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. KRAS G12D Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL KRAS INHIBITORS MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Indication
• 5.2. Non-Small Cell Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Pancreatic Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Biliary Tract Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL KRAS INHIBITORS MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Age Group
• 6.2. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL KRAS INHIBITORS MARKET: BY TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Type
• 7.2. KRAS G12C Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. KRAS G12D Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL KRAS INHIBITORS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Route Of Administration
• 8.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL KRAS INHIBITORS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Distribution Channel
• 9.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Specialty Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Retail & Drug Store Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL KRAS INHIBITORS MARKET: BY REGION 2022-2034 (USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Drug
  • 10.2.2 By Disease Indication
  • 10.2.3 By Age Group
  • 10.2.4 By Type
  • 10.2.5 By Route Of Administration
  • 10.2.6 By Distribution Channel
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Drug
  • 10.3.2 By Disease Indication
  • 10.3.3 By Age Group
  • 10.3.4 By Type
  • 10.3.5 By Route Of Administration
  • 10.3.6 By Distribution Channel
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Drug
  • 10.4.2 By Disease Indication
  • 10.4.3 By Age Group
  • 10.4.4 By Type
  • 10.4.5 By Route Of Administration
  • 10.4.6 By Distribution Channel
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Drug
  • 10.5.2 By Disease Indication
  • 10.5.3 By Age Group
  • 10.5.4 By Type
  • 10.5.5 By Route Of Administration
  • 10.5.6 By Distribution Channel
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Drug
  • 10.6.2 By Disease Indication
  • 10.6.3 By Age Group
  • 10.6.4 By Type
  • 10.6.5 By Route Of Administration
  • 10.6.6 By Distribution Channel
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL KRAS INHIBITORS INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Amgen Inc
  • 12.2.2 Bristol Myers Squibb Company
  • 12.2.3 Innovent Biologics Inc
  • 12.2.4 InventisBio Co. Ltd
  • 12.2.5 Jacobio Pharmaceuticals Group Co. Ltd
  • 12.2.6 Revolution Medicines Inc
  • 12.2.7 F. Hoffmann-La Roche Ltd
  • 12.2.8 Eli Lilly And Company
  • 12.2.9 Astellas Pharma Inc
  • 12.2.10 Bayer AG
  • 12.2.11 Mirati Therapeutics Inc
  • 12.2.12 Novartis AG
  • 12.2.13 Pfizer Inc
  • 12.2.14 Merck & Co. Inc
  • 12.2.15 AstraZeneca PLC
  • 12.2.16 Boehringer Ingelheim International GmbH
  • 12.2.17 Johnson & Johnson
  • 12.2.18 AbbVie Inc
  • 12.2.19 Genentech Inc
  • 12.2.20 BeiGene Ltd